Transparency and Control in the R&D Project Portfolio
Pharmaceutical company with a broad R&D project portfolio
Insufficient project management practices and a lack of transparency hampered decisions and resource allocation in the R&D portfolio.
The challenge
The situation
Insufficient project management practices and a lack of transparency hampered decision-making and resource allocation in the R&D portfolio. The missing overview impaired the ability to innovate and bring new products to market efficiently.
Our approach
What we delivered
Identification of the bottlenecks in the project portfolio, because without an overview it was not apparent where resources were lacking.
Assessment of resource needs across the projects
Development of cross-functional control strategies together with the functions, because a prioritization imposed from outside does not hold in an R&D portfolio.
The outcome
Results & impact
Portfolio-wide project overview
Transparent overview of the entire R&D project portfolio created.
Assessment per project
Rating of innovativeness and probability of success per project.
In summary
The company has a transparent, portfolio-wide project overview and can prioritize R&D projects by innovativeness and probability of success.
Related expertise
Research & Development and Engineering →
Support across the entire development cycle, from feasibility to design controls
Clinical Project Management →
Operational trial leadership with milestone and budget control, plus CRO oversight
Reporting & Dashboards →
Automated reporting from connected ERP and QMS systems
Continuous Improvement Programs →
Rapid improvement workshops connected to change control in the GMP environment
Similar projects
More on Pharma →Sources
- Entourage project experience (anonymized)
Your project
A comparable project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +41 61 271 23 80
info@theentourage.ch
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences



